MFN News Items

20 January, 2021

Regulatory

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...

12 January, 2021

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...

4 January, 2021

Ablivas KL1333 heading for phase II/III in 2021

Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including ...